October 3, 2006
The first involves the nation's science agenda. The second involves individual access to the right medications for treatment under Medicare, Medicaid and the Veterans Administration—which is expected to fuel ongoing federal and state political battles.
In April 2006, Jeffery Lieberman, M.D., Chairman of the Columbia University Department of Psychiatry—who heads a series of studies on schizophrenia funded by the National Institute of Mental Health (NIMH) which has made findings similar to those of the British study (and who wrote an editorial that accompanied its publication)—warned:
"The most important message of the results is the need for better treatments. Until we have those new treatments, given the substantial limitations of current medications and the diversity of patient response, clinicians need a broad range of treatment options, not restrictions on choices."
"It is essential that science and access to care not be confused, and that key distinctions, limitations and flaws in the study not be overlooked," said NAMI executive director Michael J. Fitzpatrick.
"For science and medicine, the study reflects much of NAMI's research agenda and points to the need for the President and Congress to push harder for investment in long-term, independent and comprehensive studies."
"There is a need for a more effective, third generation of medications that can ultimately lead to a cure for schizophrenia, one of the most severe mental illnesses," said NAMI medical director
"For Medicare, Medicaid, and the Department of Veterans Affairs, it would be a grave mistake to use the study to restrict access to newer medications, based on general findings that older medications seem to work as well as the newest generation," Duckworth said.
"General findings cannot be substituted for specific choices made in treating individuals with schizophrenia. One size does not fit all. It is critical that the study's limitations be recognized."
For one, the British study relies heavily on an older drug, sulpiride that has never been approved by the Food & Drug Administration (FDA) and is unavailable in the
"It is important to note that the study focuses only on medication," Duckworth said. "This is only one dimension of discussion for policymakers. Treatment of schizophrenia also requires psychosocial interventions, such as
"Finding the right medication may be the cornerstone in building the right foundation for recovery for an individual. If you don get the medication right, you run up costs elsewhere. That's another reason that unrestricted access to both old and new medications is a critical factor for budget concerns."
"It is important too to understand that one-year studies still do not tell us much about the treatment of any mental illness over time," Duckworth said.
"We need a comprehensive study to track the progress of a
Directed by the National Heart, Lung and Blood Institute, the FHS is a landmark study begun in 1948 that continues today. Approximately 12,000 residents of